NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lionheart Health's Bioelectric Platform for Enhanced Peptide Delivery in Longevity Therapies
New intellectual property spans oral, topical, and injectable peptides, with a focus on improving the efficiency of Klotho-based longevity interventions.
TL;DR
Lionheart Health's bioelectric platform could provide a competitive edge by enabling lower peptide doses with up to 300% greater efficacy across multiple delivery methods.
The technology uses controlled bioelectric stimulation to enhance transmembrane transport, barrier permeability, and receptor sensitization, improving peptide uptake and biological effectiveness.
This innovation could make longevity treatments more accessible and effective, potentially improving healthspan and quality of life for aging populations worldwide.
Bioelectric stimulation can boost peptide absorption by up to 300%, turning science fiction into reality for enhanced longevity therapies.
Found this article helpful?
Share it with your network and spread the knowledge!
Lionheart Health, through Leonhardt Ventures LLC, has filed a provisional patent application for a bioelectric stimulation platform designed to enhance peptide uptake and biological effectiveness across oral, topical, and injectable delivery methods.
It addresses a persistent challenge in biotech and longevity medicine: translating promising peptide biology into consistent outcomes, as current delivery methods lose up to 70% of IV delivery and up to 99.9% of oral and topical deliveries.
The platform applies precisely tuned bioelectric signals to enhance barrier transport, receptor interaction, and downstream tissue-level effects. Specific mechanisms include modulating membrane potential to facilitate peptide passage and creating temporary, reversible changes to tight junction behavior in the gut and skin.
It is designed to support muscle, brain, immune, metabolic, aesthetic, cardiovascular, and regenerative health, with a special emphasis on enhancing Klotho activity—a protein linked to aging regulation and cellular resilience.
The innovation is from Lionheart Health, Inc., via Leonhardt Ventures LLC, with Howard J. Leonhardt cited as the Executive Chairman, Inventor, and co-CEO of Lionheart Health and CEO of Leonhardt Ventures.
Early experimental data indicates improvements in peptide efficacy and uptake of up to 300 percent, which may enable lower dosing while maintaining or increasing therapeutic impact.
The platform aims to improve efficiency across pathways including klotho, sirtuins, sestrins, apelin, LIM, BDNF, SDF1, PDGF, VEGF, S100a, and related proteins.
Lionheart Health is recognized for leadership in klotho-based longevity research, holds multiple issued patents related to klotho technologies, and was recently named a Top 40 semifinalist in the XPRIZE Healthspan competition.
The broad coverage (oral, topical, and injectable) makes advanced peptide-based longevity interventions more efficient, predictable, and scalable across administration methods, according to the company.
Curated from Newsworthy.ai
